Lead strategic Cardiometabolic drug development design, delivering tailored, asset-focused solutions across liver diseases including MASLD/MASH, alcohol-associated liver disease (ALD), cirrhosis, viral hepatitis, and other chronic and rare liver conditions like PBC, PSC, PFIC. Strong understanding of Cardiometabolic clinical trial design, biomarkers, endpoints (e.g., fibrosis staging, histologic and non-invasive markers), and evolving therapeutic landscapes (e.g., MASLD/MASH, alcohol-associated liver disease (ALD), cirrhosis, immuno-Cardiometabolic approaches and antiviral therapies).